Coya Therapeutics, Inc. (COYA)
2.80
-0.01
(-0.36%)
USD |
NASDAQ |
Nov 06, 10:21
Coya Therapeutics Net Income (Quarterly) : -6.638M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.638M |
| March 31, 2026 | -7.207M |
| December 31, 2025 | -5.708M |
| September 30, 2025 | -2.116M |
| June 30, 2025 | -6.095M |
| March 31, 2025 | -7.307M |
| December 31, 2024 | -2.916M |
| September 30, 2024 | -4.021M |
| June 30, 2024 | -2.892M |
| Date | Value |
|---|---|
| March 31, 2024 | -5.052M |
| December 31, 2023 | 1.266M |
| September 30, 2023 | -3.422M |
| June 30, 2023 | -3.095M |
| March 31, 2023 | -2.736M |
| December 31, 2022 | -3.108M |
| September 30, 2022 | -4.021M |
| December 31, 2021 | -1.630M |
| September 30, 2021 | -1.33M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 0.2437M |
| Total Expenses (Quarterly) | 6.882M |
| EPS Diluted (Quarterly) | -0.283 |
| Enterprise Value | 22.74M |
| Gross Profit Margin (Quarterly) | 98.85% |
| Profit Margin (Quarterly) | -2.72K% |
| Earnings Yield | -35.73% |
| Normalized Earnings Yield | -32.83 |